An ultra-low dose of tetrahydrocannabinol provides cardioprotection

Biochemical Pharmacology

Volumn 85, Issue 11, 2013, Pages 1626-1633

  Waldman, M ^a   Hochhauser, E ^a,c   Fishbein, M ^b,c   Aravot, D ^a,c   Shainberg, A ^d   Sarne, Y ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b Adelson Center for the Biology of Addictive Diseases   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

Author keywords

Cannabinods; Cardioprotection; Ischemia; Tetrahydrocannabiol (THC)

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; TETRAHYDROCANNABINOL; TROPONIN T;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; PHOSPHORYLATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877597866     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.03.014     Document Type: Article

References (35)

1. C.J. Murray, and A.D. Lopez Mortality by cause for eight regions of the world: Global Burden of Disease Study Lancet 349 1997 1269 1276
2. C.J. Murray, and A.D. Lopez Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study Lancet 349 1997 1436 1442
3. R.B. Jennings, C.E. Murry, C. Steenbergen Jr., and K.A. Reimer Development of cell injury in sustained acute ischemia Circulation 82 1990 II2 II12
4. N.G. Frangogiannis The immune system and cardiac repair Pharmacol Res 58 2008 88 111
5. C.E. Murry, R.B. Jennings, and K.A. Reimer Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74 1986 1124 1136
6. D.J. Hausenloy, and D.M. Yellon Preconditioning and postconditioning: underlying mechanisms and clinical application Atherosclerosis 204 2009 334 341
7. D.M. Yellon, and J.M. Downey Preconditioning the myocardium: from cellular physiology to clinical cardiology Physiol Rev 83 2003 1113 1151
8. S. Lecour, and R.W. James When are pro-inflammatory cytokines SAFE in heart failure Eur Heart J 32 2011 680 685
9. D.J. Hausenloy, S. Lecour, and D.M. Yellon Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin Antioxid Redox Signal 14 2011 893 907
10. S. Lecour Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway J Mol Cell Cardiol 47 2009 32 40
11. J.S. Choi, H.Y. Kim, J.H. Cha, and M.Y. Lee Ischemic preconditioning- induced activation of ERK1/2 in the rat hippocampus Neurosci Lett 409 2006 187 191
12. Z. Gu, Q. Jiang, and G. Zhang Extracellular signal-regulated kinase and c-Jun N-terminal protein kinase in ischemic tolerance Neuroreport 12 2001 3487 3491
13. P. Lepicier, C. Lagneux, M.G. Sirois, and D. Lamontagne Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts Life Sci 81 2007 1373 1380
14. J.F. Bouchard, P. Lepicier, and D. Lamontagne Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart Life Sci 72 2003 1859 1870
15. Y.A. Shmist, I. Goncharov, M. Eichler, V. Shneyvays, A. Isaac, and Z. Vogel Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production Mol Cell Biochem 283 2006 75 83
16. P. Pacher, and G. Hasko Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning Br J Pharmacol 153 2008 252 262
17. F. Assaf, M. Fishbein, M. Gafni, O. Keren, and Y. Sarne Pre- and post-conditioning treatment with an ultra-low dose of Delta9- tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage Behav Brain Res 220 2011 194 201
18. Y. Sarne, F. Asaf, M. Fishbein, M. Gafni, and O. Keren The dual neuroprotective-neurotoxic profile of cannabinoid drugs Br J Pharmacol 163 2011 1391 1401
19. M. Fishbein, S. Gov, F. Assaf, M. Gafni, O. Keren, and Y. Sarne Long-term behavioral and biochemical effects of an ultra-low dose of Delta(9)- tetrahydrocannabinol (THC): neuroprotection and ERK signaling Exp Brain Res 221 2008 437 448
20. E. Hochhauser, Y. Cheporko, N. Yasovich, L. Pinchas, D. Offen, and Y. Barhum Bax deficiency reduces infarct size and improves long-term function after myocardial infarction Cell Biochem Biophys 47 2007 11 20
21. X.M. Gao, A.M. Dart, E. Dewar, G. Jennings, and X.J. Du Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice Cardiovasc Res 45 2000 330 338
22. E. Hochhauser, S. Kivity, D. Offen, N. Maulik, H. Otani, and Y. Barhum Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice Am J Physiol Heart Circ Physiol 284 2003 H2351 H2359
23. F. Montecucco, S. Lenglet, V. Braunersreuther, F. Burger, G. Pelli, and M. Bertolotto CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion J Mol Cell Cardiol 46 2009 612 620
24. R. Durst, H. Danenberg, R. Gallily, R. Mechoulam, K. Meir, and E. Grad Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury Am J Physiol Heart Circ Physiol 293 2007 H3602 H3607
25. N. Defer, J. Wan, R. Souktani, B. Escoubet, M. Perier, and P. Caramelle The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy FASEB J 23 2009 2120 2130
26. C. Di Filippo, F. Rossi, S. Rossi, and M. D'Amico Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN J Leukoc Biol 75 2004 453 459
27. A.V. Krylatov, D.S. Ugdyzhekova, N.A. Bernatskaya, L.N. Maslov, R. Mekhoulam, and R.G. Pertwee Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion Bull Exp Biol Med 131 2001 523 525
28. D.S. Ugdyzhekova, A.V. Krylatov, N.A. Bernatskaya, L.N. Maslov, R. Mechoulam, and R.G. Pertwee Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis Bull Exp Biol Med 133 2002 125 126
29. S.K. Walsh, C.Y. Hepburn, K.A. Kane, and C.L. Wainwright Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion Br J Pharmacol 160 2010 1234 1242
30. U. Limbruno, R. Zucchi, S. Ronca-Testoni, P. Galbani, G. Ronca, and M. Mariani Sarcoplasmic reticulum function in the stunned myocardium J Mol Cell Cardiol 21 1989 1063 1072
31. R. Cohen, A. Shainberg, E. Hochhauser, Y. Cheporko, A. Tobar, and E. Birk UTP reduces infarct size and improves mice heart function after myocardial infarct via P2Y2 receptor Biochem Pharmacol 82 2011 1126 1133
32. O.V. Lasukova, L.N. Maslov, S. Ermakov, D. Crawford, F. Barth, and A.V. Krylatov [Role of cannabinoid receptors in regulation of cardiac tolerance to ischemia and reperfusion] Izv Akad Nauk Ser Biol 2008 471 478
33. M. Behrends, R. Schulz, H. Post, A. Alexandrov, S. Belosjorow, and M.C. Michel Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs Am J Physiol Heart Circ Physiol 279 2000 H1111 H1119
34. P. Lepicier, J.F. Bouchard, C. Lagneux, and D. Lamontagne Endocannabinoids protect the rat isolated heart against ischaemia Br J Pharmacol 139 2003 805 815
35. Y.H. He, H.N. Zhang, G.P. Zhang, N. Hou, Q. Xiao, and Y. Huang A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: roles of extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB Clin Exp Pharmacol Physiol 38 2011 739 746